Nigeria Confirms Ebola Case in FCT, Activates Response
Nigeria confirms Ebola case in FCT after lab tests verify diagnosis of a female traveler from Uganda. Health authorities activate response protocols.
Featured Stories
All Stories →
Kano residents suffer from unsafe, polluted tap water
Kano residents face severe health risks from unsafe tap water, including cholera, after years of pollution and inadequate treatment.
Free Ambulance Service Saves Lives in Yobe State
Yobe State's free ambulance service is saving lives by providing critical access to emergency medical care.
Kano’s Ghari Community Trained to Recognize Prolonged Labor
Kano's Ghari community is trained to recognize prolonged labor warning signs and seek timely medical care through art-based initiatives.
Diet Links
More →
Monitor Picks
More →
Free Ambulance Service Saves Lives in Yobe State
Nigeria Struggles to Fund Maternal Health Services
West Africa seeks Lassa fever vaccine funding
BP Trends
More →
Drug Doses
More →
Stress Checks
More →
Popular Posts
Refresh ↺Scientists Identify New Pathway to Combat Liver Inflammation
Researchers find hormone GDF15 triggers a brain‑to‑liver pathway that cuts liver inflammation and fibrosis, offering therapy even without weight loss.
The Benefits of Acupuncture: How It Can Help Your Body
Acupuncture has been practiced for centuries and is one of the oldest forms of medicine. It is an important part…
Hip fracture death risk higher with low education
Low education is linked to significantly higher hip fracture death risk after surgery. New study highlights socioeconomic factors in patient…
6 Advantages Of Pursuing A Pharmaceutical Career
The pharmaceutical industry is one of the fastest-growing industries today. Discoveries and innovations are being made every day. Some of…
Uncovering the 5 Surprising Benefits of Osteopathy
Osteopathy is an alternative medical treatment that has been around for centuries and is becoming increasingly popular due to its…
Breakthrough pancreatic cancer drug doubles survival in late-stage patients
FDA-approved daraxonrasib may double survival for late-stage pancreatic cancer patients after chemotherapy failure, per University of Chicago trial data.